SCHEMBL3974751

SCHEMBL3974751

Cc1ccc(C)c(-n2nc(C3(C(F)(F)F)CC3)cc2Nc2ncccc2C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ6 P48051 9/20 0.47
KCNJ5 P48544 9/20 0.47
KCNJ3 P48549 9/20 0.47
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
DHODH Q02127 5/20 0.42
PKM P14618 2/20 0.42
GMNN O75496 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TTR P02766 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
NFKB1 P19838 1/20 0.42
UGT1A1 P22309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979286 0.81 LMNA (0.51) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3859778 0.79 LMNA (0.50) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3976262 0.78 LMNA (0.49) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3861464 0.78 DHODH (0.48) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3977181 0.77 LMNA (0.48) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3864506 0.75 MAPK14 (0.48) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3976410 0.74 LMNA (0.47) LMNAGAAMEN1KMT2ANPC1
SCHEMBL3974247 0.74 RAB9A (0.52) LMNANPC1MAPTRAB9AALDH1A1
SCHEMBL5012147 0.73 KCNJ6 (0.53) KCNJ6KCNJ5KCNJ3LMNAMEN1
SCHEMBL3974469 0.72 MAPK14 (0.46) LMNAMEN1KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP KCNJ6 1859/4885KCNJ5 1245/4885KCNJ3 1054/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP KCNJ6 1859/4885KCNJ5 1245/4885KCNJ3 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.